Mitiglinide

Drug Profile

Mitiglinide

Alternative Names: Glinsuna; Glufast; KAD-1229; Kuai ruo tuo; S 21403

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Aichi Gakuin University; Eisai Co Ltd; Elixir Pharmaceuticals; Hikma Pharmaceuticals; JW Pharmaceutical; Kissei Pharmaceutical; Orient Europharma; Takeda; USV
  • Class Amides; Antihyperglycaemics; Butyric acids; Isoindoles; Small molecules
  • Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 May 2017 Aichi Medical University School of Medicine and Kissei Pharmaceutical complete a clinical trial in Type-2 diabetes mellitus in Japan (UMIN000019833)
  • 17 Jun 2016 Launched for Type-2 diabetes mellitus in Japan (PO; Fast dissolve)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top